Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset

Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset

Introduction: The phase 3 RELAY global study (NCT02411448) revealed significant improvement in progression-free survival (PFS) with ramucirumab plus erlotinib (RAM + ERL) compared with placebo plus ERL (PL + ERL) in untreated EGFR-mutated metastatic NSCLC (hazard ratio [HR] = 0.59 [95% confidence in...

Full description

Bibliographic Details
Main Authors: Kazuto Nishio, MD, PhD, Takashi Seto, MD, Makoto Nishio, MD, PhD, Martin Reck, MD, PhD, Edward B. Garon, MD, MS, Kazuko Sakai, PhD, Koichi Goto, MD, PhD, Terufumi Kato, MD, Yoichi Nakanishi, MD, PhD, Toshiaki Takahashi, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Katsuyuki Kiura, MD, PhD, Yuichiro Ohe, MD, PhD, Tomohide Tamura, MD, Carla Visseren-Grul, MD, Bente Frimodt-Moller, MSc, Rebecca R. Hozak, PhD, Sameera R. Wijayawardana, PhD, Annamaria Zimmermann, MS, Gosuke Homma, PhD, Sotaro Enatsu, MD, PhD, Kazuhiko Nakagawa, MD, PhD
Format: Article
Language:English
Published: Elsevier 2021-06-01
Series:JTO Clinical and Research Reports
Subjects:
Circulating tumor DNA
EGFR
Non–small cell lung cancer
Japan
Ramucirumab
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364321000308

Internet

http://www.sciencedirect.com/science/article/pii/S2666364321000308

Similar Items